Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

176 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Plasmodium falciparum malaria vaccines in development.
Vekemans J, Ballou WR. Vekemans J, et al. Expert Rev Vaccines. 2008 Mar;7(2):223-40. doi: 10.1586/14760584.7.2.223. Expert Rev Vaccines. 2008. PMID: 18324891 Review.
Recombinant bacillus Calmette-Guérin as a potential vector for preventive HIV type 1 vaccines.
Falk LA, Goldenthal KL, Esparza J, Aguado MT, Osmanov S, Ballou WR, Beddows S, Bhamarapravati N, Biberfeld G, Ferrari G, Hoft D, Honda M, Jackson A, Lu Y, Marchal G, McKinney J, Yamazaki S. Falk LA, et al. AIDS Res Hum Retroviruses. 2000 Jan 20;16(2):91-8. doi: 10.1089/088922200309421. AIDS Res Hum Retroviruses. 2000. PMID: 10659047
Protection of humans against malaria by immunization with radiation-attenuated Plasmodium falciparum sporozoites.
Hoffman SL, Goh LM, Luke TC, Schneider I, Le TP, Doolan DL, Sacci J, de la Vega P, Dowler M, Paul C, Gordon DM, Stoute JA, Church LW, Sedegah M, Heppner DG, Ballou WR, Richie TL. Hoffman SL, et al. J Infect Dis. 2002 Apr 15;185(8):1155-64. doi: 10.1086/339409. Epub 2002 Apr 1. J Infect Dis. 2002. PMID: 11930326
Pre-erythrocytic malaria vaccines to prevent Plasmodium falciparum malaria.
Ballou WR, Kester KE, Heppner DG. Ballou WR, et al. Chem Immunol. 2002;80:253-61. Chem Immunol. 2002. PMID: 12058643 Review. No abstract available.
Phase 1/2a Trial of Plasmodium vivax Malaria Vaccine Candidate VMP001/AS01B in Malaria-Naive Adults: Safety, Immunogenicity, and Efficacy.
Bennett JW, Yadava A, Tosh D, Sattabongkot J, Komisar J, Ware LA, McCarthy WF, Cowden JJ, Regules J, Spring MD, Paolino K, Hartzell JD, Cummings JF, Richie TL, Lumsden J, Kamau E, Murphy J, Lee C, Parekh F, Birkett A, Cohen J, Ballou WR, Polhemus ME, Vanloubbeeck YF, Vekemans J, Ockenhouse CF. Bennett JW, et al. PLoS Negl Trop Dis. 2016 Feb 26;10(2):e0004423. doi: 10.1371/journal.pntd.0004423. eCollection 2016 Feb. PLoS Negl Trop Dis. 2016. PMID: 26919472 Free PMC article. Clinical Trial.
Sequential Phase 1 and Phase 2 randomized, controlled trials of the safety, immunogenicity and efficacy of combined pre-erythrocytic vaccine antigens RTS,S and TRAP formulated with AS02 Adjuvant System in healthy, malaria naïve adults.
Kester KE, Gray Heppner D Jr, Moris P, Ofori-Anyinam O, Krzych U, Tornieporth N, McKinney D, Delchambre M, Ockenhouse CF, Voss G, Holland C, Beckey JP, Ballou WR, Cohen J; RTS,S/TRAP Group. Kester KE, et al. Vaccine. 2014 Nov 20;32(49):6683-91. doi: 10.1016/j.vaccine.2014.06.033. Epub 2014 Jun 18. Vaccine. 2014. PMID: 24950358 Clinical Trial.
Extended safety, immunogenicity and efficacy of a blood-stage malaria vaccine in malian children: 24-month follow-up of a randomized, double-blinded phase 2 trial.
Laurens MB, Thera MA, Coulibaly D, Ouattara A, Kone AK, Guindo AB, Traore K, Traore I, Kouriba B, Diallo DA, Diarra I, Daou M, Dolo A, Tolo Y, Sissoko MS, Niangaly A, Sissoko M, Takala-Harrison S, Lyke KE, Wu Y, Blackwelder WC, Godeaux O, Vekemans J, Dubois MC, Ballou WR, Cohen J, Dube T, Soisson L, Diggs CL, House B, Bennett JW, Lanar DE, Dutta S, Heppner DG, Plowe CV, Doumbo OK. Laurens MB, et al. PLoS One. 2013 Nov 18;8(11):e79323. doi: 10.1371/journal.pone.0079323. eCollection 2013. PLoS One. 2013. PMID: 24260195 Free PMC article. Clinical Trial.
Results from tandem Phase 1 studies evaluating the safety, reactogenicity and immunogenicity of the vaccine candidate antigen Plasmodium falciparum FVO merozoite surface protein-1 (MSP1(42)) administered intramuscularly with adjuvant system AS01.
Otsyula N, Angov E, Bergmann-Leitner E, Koech M, Khan F, Bennett J, Otieno L, Cummings J, Andagalu B, Tosh D, Waitumbi J, Richie N, Shi M, Miller L, Otieno W, Otieno GA, Ware L, House B, Godeaux O, Dubois MC, Ogutu B, Ballou WR, Soisson L, Diggs C, Cohen J, Polhemus M, Heppner DG Jr, Ockenhouse CF, Spring MD. Otsyula N, et al. Malar J. 2013 Jan 23;12:29. doi: 10.1186/1475-2875-12-29. Malar J. 2013. PMID: 23342996 Free PMC article. Clinical Trial.
Recombinant Liver Stage Antigen-1 (LSA-1) formulated with AS01 or AS02 is safe, elicits high titer antibody and induces IFN-gamma/IL-2 CD4+ T cells but does not protect against experimental Plasmodium falciparum infection.
Cummings JF, Spring MD, Schwenk RJ, Ockenhouse CF, Kester KE, Polhemus ME, Walsh DS, Yoon IK, Prosperi C, Juompan LY, Lanar DE, Krzych U, Hall BT, Ware LA, Stewart VA, Williams J, Dowler M, Nielsen RK, Hillier CJ, Giersing BK, Dubovsky F, Malkin E, Tucker K, Dubois MC, Cohen JD, Ballou WR, Heppner DG Jr. Cummings JF, et al. Vaccine. 2010 Jul 12;28(31):5135-44. doi: 10.1016/j.vaccine.2009.08.046. Epub 2009 Sep 6. Vaccine. 2010. PMID: 19737527 Clinical Trial.
Plasmodium falciparum-specific cellular immune responses after immunization with the RTS,S/AS02D candidate malaria vaccine in infants living in an area of high endemicity in Mozambique.
Barbosa A, Naniche D, Aponte JJ, Manaca MN, Mandomando I, Aide P, Sacarlal J, Renom M, Lafuente S, Ballou WR, Alonso PL. Barbosa A, et al. Infect Immun. 2009 Oct;77(10):4502-9. doi: 10.1128/IAI.00442-09. Epub 2009 Aug 3. Infect Immun. 2009. PMID: 19651872 Free PMC article. Clinical Trial.
176 results
Jump to page
Feedback